Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Micelles in Advanced Solid Tumors
NCT04778839Phase 1Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2021
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Paclitaxel Micelles for Injection in solid tumor (advanced stage), breast cancer, ovarian cancer and 2 more (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 2 years, Dose Limiting Toxicity at 2 years and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04778839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778839.